Suppr超能文献

该基因中的G199X和V157fs突变促进浆液性卵巢癌的恶性发展:一项使用全外显子组测序的分析。

The G199X and V157fs mutations in the gene promote malignancy in serous ovarian cancer: an analysis using whole-exome sequencing.

作者信息

Su Dan, Nie Man, Yue Jun

机构信息

Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.

Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.

出版信息

Ann Transl Med. 2021 Apr;9(8):710. doi: 10.21037/atm-21-583.

Abstract

BACKGROUND

The carcinogenic mechanisms underlying serous ovarian cancer are not fully understood.

METHODS

Whole-exome sequencing and targeted sequencing were performed in ovarian cancer samples to identify novel molecular markers involved in the process of cell malignancy in ovarian cancer. experiments, the oncogenic roles such as cell proliferation, migration and invasion of G199X and V157fs mutations were investigated deeply.

RESULTS

The present study identified the G199X and V157fs point mutations in the tumor protein P53 gene (). The rate of mutation was 59.2% in a cohort of 76 ovarian cancer patients, compared with 9.0% in a cohort of 156 healthy women. Kaplan-Meier analysis showed that patients with a mutation had a lower 5-year overall survival (OS) rate compared with patients harboring wild type . experiments in an ovarian cancer cell line demonstrated that the G199X and V157fs mutants inhibited P53 protein expression, enhanced proliferation, promoted migration and increased invasion.

CONCLUSIONS

This study identified two novel markers, G199X and V157fs mutations in . Functional assays indicated that these mutations enhanced the malignant phenotype in ovarian cancer cells. These novel markers will assist in the diagnosis of ovarian tumors and represent potential targets for the treatment of mutant ovarian cancers.

摘要

背景

浆液性卵巢癌的致癌机制尚未完全明确。

方法

对卵巢癌样本进行全外显子测序和靶向测序,以鉴定参与卵巢癌细胞恶性转化过程的新型分子标志物。通过实验,深入研究了G199X和V157fs突变在细胞增殖、迁移和侵袭等致癌作用。

结果

本研究在肿瘤蛋白P53基因中鉴定出G199X和V157fs点突变。在76例卵巢癌患者队列中,突变率为59.2%,而在156名健康女性队列中为9.0%。Kaplan-Meier分析显示,与携带野生型P53的患者相比,携带P53突变的患者5年总生存率较低。在卵巢癌细胞系中的实验表明,G199X和V157fs突变体抑制P53蛋白表达,增强增殖,促进迁移并增加侵袭。

结论

本研究鉴定出两个新型标志物,即P53基因中的G199X和V157fs突变。功能分析表明,这些突变增强了卵巢癌细胞的恶性表型。这些新型标志物将有助于卵巢肿瘤的诊断,并代表P53突变型卵巢癌治疗的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8dd/8106005/e66aaa5226ee/atm-09-08-710-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验